It is therefore plausible that the absence of membrane ERα activation by E4, as documented by Abot et al. [9] in the endothelium, contributes to the differential effect of E4 versus E2 on breast cancer cells in vitro and tumor progression in vivo. The gene discussed is ESR1; the disease is neoplasm.